FBRX · Forte Biosciences, Inc.
$76.95
+0.06 (+0.07%)
At close · Aug 21
Market Cap
$1.63B
Shares
21.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$76.89
Open$76.93
Day$76.82–76.95
52W close$10.30–76.98
Avg vol 30d2.1M
Short int1.9M · 9.0% float · 1.0d
Short vol39%
Last earningsMay 10, 2021
DataAug 2024–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Aug 28, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+149%
above
Price vs 50-day avg
+60%
above
RSI (14)
84
overbought
MACD trend
Negative
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+29%
trailing
6-month return
+154%
trailing
YTD return
+182%
this year
Relative strength
+143%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $48 › 200d $31 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.97% of float · ▼ -7.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
85 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+61%
Y/Y
Free cash flow
$-51.0M
Balance sheet
$50.8M
net cash
Quant / Vol
risk profile
Volatility
130%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
2.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+149%
Bullish
Price vs 50-day avg
+60%
Bullish
RSI (14)
84
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $48 › 200d $31 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.97% of float · ▼ -7.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
85 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10
Now $77 · 100%
Range high $77
vs 200-day avg +149%
vs 50-day avg +60%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FBRX
this stock
Forte Biosciences, Inc.
|
$1.63B | +182.0% | -99.8% | — | 9.0% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Aug 28, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FBRX | +0.0% | +28.8% | +154.4% | +0.4% | +182.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.0% | +25.5% | +143.3% | -1.7% | +170.1% |
Key facts
CIK
1419041
CUSIP
34962G208
13F (30d)
93 filings
89 filers
Visit website
Investor relations